Teva, Lupin Settle Patent Suit on Austedo Movement Disorder Drug

Teva Pharmaceuticals Industries Ltd. settled a patent-infringement lawsuit over Lupin Ltd.’s proposed generic version of Austedo, used to treat tardive dyskinesia and Huntington’s disease chorea.

Teva announced the agreement Monday. The parties filed a stipulation and proposed order of dismissal Monday afternoon, but Chief Judge Freda L. Wolfson of the U.S. District Court for the District of New Jersey hasn’t yet approved it.

Teva said in its announcement that the deal grants Lupin a license to sell its copycat beginning in April 2033, or earlier under certain circumstances. Teva cited a U.S. Patent and Trademark Office tribunal’s March 9 decision ...